
Hagop Kantarjian/mdanderson.org
Feb 26, 2025, 10:02
Hagop Kantarjian: Updated results of our frontline trial of FLAG-IDA+VEN
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues published in Leukemia:
“Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed AML. Responses were seen across all ELN22 risk groups, with 90% MRD neg. In RR AML, 79% first salvage and TP53wt attained CRc.”
Authors: Courtney DiNardo, Wei-Ying Jen, Koichi Takahashi, Marina Konopleva, Hagop Kantarjian et al.
More posts featuring Hagop Kantarjian.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 26, 2025, 10:02
Feb 26, 2025, 10:01
Feb 26, 2025, 09:56
Feb 26, 2025, 09:50
Feb 26, 2025, 09:46
Feb 26, 2025, 09:43
Feb 26, 2025, 09:41